Despite considerable progress in cancer treatment, unwanted side effects remain a significant challenge. Many anticancer therapies interact with molecules beyond their intended target, reducing treatment precision and contributing to adverse events that can affect both patients and long-term outcomes.
Improving target specificity remains one of the key opportunities in oncology. More precise therapies have the potential to maintain strong anti-cancer activity while reducing unwanted effects and expanding treatment options.
At Selecta Biotech, we are addressing this challenge through ESiNAR-X®, our proprietary oligonucleotide platform. By improving the precision of RNA-targeted therapeutics, we aim to develop safer and more effective treatments for patients with cancer.
Chronic myeloid leukemia (CML) is a blood cancer driven by a well-defined genetic abnormality that causes the uncontrolled growth of white blood cells. Advances in understanding the biology of CML led to the development of tyrosine kinase inhibitors (TKIs), transforming the disease from a life-threatening diagnosis into a manageable condition for many patients.
Despite this success, important challenges remain. Around 20 to 30% of patients develop resistance to treatment or do not respond adequately to available therapies during the course of their disease. These patients continue to need new treatment options with different mechanisms of action.
Previous oligonucleotide approaches have demonstrated the potential of RNA-targeted therapies while revealing important challenges. ASP210 was designed to address these limitations through the ESiNAR-X® platform.